Hepatitis C regimens containing ledipasvir/sofosbuvir (Harvoni) or paritaprevir/ritonavir/ombitasvir and dasabuvir (Viekira Pak) cured almost 17,500 patients in the Veterans Affairs (VA) health care system.
MK3, a fixed-dose combination of three direct-acting antivirals (DAAs) with different mechanisms of action, provided cure rates exceeding 95% in patients with hepatitis C genotypes 1, 2, or 3.
Hepatitis C cure rates with ledipasvir/sofosbuvir (Harvoni) proved nearly identical in patients treated by hepatitis specialists, by primary care providers or by nurse practitioners.
A comprehensive, coordinated care program implemented by the New York City Department of Health appeared to reduce barriers to HCV therapy, such as mental health conditions, alcohol or drug use, and HIV infection.
Hepatitis C cure rates using elbasvir/grazoprevir (Zepatier) was 93% in individuals with genotypes 1 or 4, in a study of patients in Asia and Russia.
Cirrhotic hepatitis-C patients in Denmark had a 63% lower risk of liver cancer and a 76% lower risk of decompensated cirrhosis if they achieved a cure with direct-acting antivirals.
Despite the diversity of new direct-acting antivirals (DAAs), a tiny number of patients are still left behind. Nancy Reau, M.D., presented a summary of soon-to-be-approved drugs that should work for these tough-to-treat patients.
Prevalence of cardiovascular disease, renal impairment and fractures or osteoporosis was higher with than without HIV every year from 2003 to 2013.
State Medicaid Programs Ease Illegal Restrictions on Hepatitis C Medications, but More Progress Needed
While restrictions for obtaining hepatitis C drugs through Medicaid programs vary state by state, restrictions eased somewhat across the country from 2014 to 2016, according to data presented at the Liver Meeting 2016.
Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) improved kidney and bone markers in a study focused on people 50 years old or older.